Liraglutide Labeling Updated With Cardiovascular Safety Data

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non-fatal stroke, CV death) in patients treated with liraglutide 1.8mg once daily or placebo.

Source link

Related posts

Could Your Racing Heart be Caused by Caffeine?


Depression and Heart Disease


Thomas Bevill Peacock and the First Descriptions of Congenital Heart Disease.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy